Some oncologists choose not to mention immunotherapy to dying patients, arguing that scientists first must gather rigorous evidence about the benefits and pitfalls, and that treating patients experimentally outside a clinical trial is perilous business. But others, like Dr. Sartor, are offering the drugs to some terminal patients as a roll of the dice. If the patient is dying and there’s a remote chance the drug will help, then why not?
For George Coukos, one of the world’s foremost experts in immunotherapy, this is “an extraordinary moment in human history” when the word “cure” can be seriously used in relation to cancer, our most feared global killer.
A RECENT survey of 400 clinical oncologists found that 80% discuss the use of medical cannabis with their patients, and although nearly 50% recommend it, fewer than 30% consider themselves knowledgeable enough to make such recommendations.1 Oncologists are perhaps among the most evidence-demanding of all medical specialists, as we deal with a serious illness and use medications with significant potential for adverse effects. We prefer to make recommendations supported by published literature. Due to the essential prohibition against conducting clinical trials demonstrating the potential therapeutic effects of botanical cannabis, such data are largely unavailable.
In recent years, Vinay Prasad, a young hematologist–oncologist at Oregon Health and Science University, has emerged as a premier critic of new directions in cancer medicine.
These experts definitely practice what they preach. Here’s how you can make these simple changes to prevent cancer too.
“I didn’t have a lot of hope at the time,” she said. “If you don’t have those mutations, you’re lucky to live a year. My oncologist sent in my test, started me on a second line of chemo, which was really awful, then three weeks later said, ‘You’re not going to believe this. You’re ALK positive.’ It was like winning the lung cancer lottery. There are so many other things available. It was a total life-changer.”
Patients refusing potentially curative treatments happen uncomfortably often. It’s understandable for elderly patients who simply don’t want to go through surgery, chemotherapy and radiation therapy.
It’s most difficult when it’s a young mother and she’s putting herself into a high risk position by refusing treatment.
Debate among doctors looks at whether zealous screening leads to overtreatment
As new cancer therapies have prolonged life, an interesting question has arisen among community oncologists: “Is it better to transfer long-term cancer survivors to general practitioners or develop clinics for long-term survivors within cancer centers?”
Despite their shaky knowledge of the drug, nearly half of all oncologists do recommend medical cannabis to their patients, according to the study, which was published Thursday in the Journal of Clinical Oncology.
Usually, I cast a calm eye on all that awaits me; after all, it’s what I’m trained for. But some days are more difficult than others.
Oncology Learning Network® is an online resource for the latest developments in oncology practice, providing a customized experience for readers to stay informed about the topics that matter most to them. Through clinical insights, peer-reviewed journal articles, interactive features, research news updates, accredited continuing educational programs, and professional live meetings and events, Oncology Learning Network serves as a collaborative learning and networking environment for a multidisciplinary community of oncology medical professionals.
The official website for the journal ONCOLOGY provides information for physicians, nurses and patients. Also features bi-daily cancer news updates.
Shaping the future of cancer care. The aim of Cancer World is to help reduce the unacceptable number of deaths from cancer that is caused by late diagnosis and inadequate cancer care. We know our success in preventing and treating cancer depends on many factors.
Independent news for the oncologist and the hematologist/oncologist.
MDedge Hematology & Oncology is the source for timely, relevant, evidence-based, practice-changing information for hematologist-oncologists and medical oncologists. Readily accessible, interactive formats make MDedge Hematology & Oncology the best way for busy specialists to stay up to date and gain the perspectives they need to provide state-of-the-art care that improves patient outcomes.
OncLive.com is the preeminent online source for physicians and other healthcare professionals who are looking for information, tools, and techniques to improve patient care. The site's unique content is organized by specialty, publication, and audience, under one customizable network, offering readers quality content in a streamlined package.
Cancer resources for patients and healthcare professionals.
The independent Hem/Onc news source.
The Cancer Letter, an independent weekly newsletter, is the leading source of information on development of cancer therapies, cancer research funding and health care finance, legislation and policy.
The aims of the European Organisation for Research and Treatment of Cancer (EORTC) are to develop, conduct, coordinate, and stimulate translational and clinical research in Europe to improve the management of cancer and related problems by increasing survival but also patient quality of life.
As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers.
Radiation Oncology Resources (ROR) is the leader in assisting radiation oncology departments with their most vexing issues and delivering customized solutions that meet both clinical and financial requirements.
The US Oncology Network believes local cancer care is better care. We empower the delivery of advanced integrated cancer care through our network of independent physicians who share expertise and resources to provide quality, value-based care close to home.
World Oncology Network is a worldwide network of communications among physicians and nurses practicing Hematology/Oncology. WON is a nonprofit organization with more than 2000 members from over 80 countries.
Whether you are in training or a fully-qualified oncology specialist, ESMO offers young oncologists a wealth of opportunities: educational courses, fellowships and workshops where you can refine your skills and gain access to the latest developments in your field.
Oncologist-approved cancer information from the American Society of Clinical Oncology.
CenterWatch provides clinical research professionals with an assortment of industry resources for all facets of the community, from in-depth market information and analysis to breaking business news and career advancement tools.
CURE Media Group’s flagship product, CURE magazine, is the indispensable guide to every stage of the cancer experience. With nearly 1 million readers, CURE is the largest consumer publication in the United States focused entirely on cancer, with broad distribution to cancer patients, cancer centers and advocacy groups.
Doctors Lounge is one of the most popular online medical resources for physicians, students and allied clinical professionals. It provides clinical information on oncology through multimedia tutorials and other study aids.
Our mission is to help clinicians efficiently understand medical developments to improve patient care and foster professional development.
MD Anderson provides clinical tools and resources to assist physicians, healthcare providers and professionals.
The latest Cancer & Oncology News articles published daily. Includes news on the physical, chemical and biologic properties and features of neoplasms, tumors, symptoms, treatments, causes and risk factors.
Oncology/Hematology Information Center from MedPage Today is the only service for physicians that provides a clinical perspective on the breaking medical news that their patients are reading.
The NSABP was one of the first organizations to undertake large-scale studies in the prevention of breast cancer, and our Breast Cancer Prevention Trial (BCPT), which included more than 13,000 women at increased risk for breast cancer, demonstrated the value of the drug tamoxifen in reducing the incidence of the disease in this population. The second prevention trial, the Study of Tamoxifen and Raloxifene (STAR) entered more than 19,000 women to compare the effects of these two drugs in reducing the incidence of breast cancer.